Mar 16, 2021
Une aide de 886 020 euros au titre du Contrat Innovation Région est attribuée pour le développement de ANT3310-MEM, un produit destiné à lutter contre les infections respiratoires acquises à l’hôpital. Labège, France, 16 Mars, 2021. Antabio SAS, société...
May 6, 2020
Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem (MEM) and the novel broad-spectrum serine beta-lactamase inhibitor...
Aug 7, 2019
On August 2, 2019. The US government announced several significant changes to hospital antibiotic reimbursement by Medicare & Medicaid (CMS) in US hospitals. Importantly, the new Policy defines rules for reimbursing new antibiotics with Qualified Infectious...
Jun 21, 2019
Antabio SAS, a private biopharmaceutical company developing novel antibacterial treatments focused on drug-resistant life-threatening infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP)...
Jul 12, 2018
Labège, France, 12th July 2018. Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today it has extended its Series A financing round with an additional €5.2 million subscribed by investment...
Jan 5, 2018
Labège, France, 05 January 2018. Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of four highly successful and accomplished biotech executives to the management...
